Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

$24.99

Return on Assets (ROA)
since 2005

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Abbott Laboratories, ROA, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in millions


The Return on Assets (ROA) exhibited considerable fluctuation over the period from 2005 to 2025. Initial values were strong, followed by periods of decline, recovery, and ultimately, a significant peak in the latter years of the observation window.

Initial Performance (2005-2006)
The ROA began at 11.57% in 2005, representing a robust level of profitability relative to asset base. A substantial decrease was observed in 2006, falling to 4.75%, indicating a diminished ability to generate earnings from assets during that year.
Recovery and Stability (2007-2010)
From 2007 through 2010, the ROA demonstrated a recovery trend, increasing from 9.08% to 10.96% and then settling at 7.78% in 2010. This period suggests a stabilization of profitability following the initial decline, although the 2010 value represents a step back from the earlier recovery peak.
Moderate Fluctuations (2011-2015)
The years 2011 to 2015 saw moderate fluctuations in ROA, ranging from 7.84% to 10.72%. While no strong directional trend was apparent, the values remained within a relatively narrow band, suggesting consistent, albeit unspectacular, asset utilization. A notable drop occurred in 2015, with the ROA falling to 2.66%.
Period of Low Returns (2016-2017)
2016 and 2017 experienced particularly low ROA values, at 2.66% and 0.63% respectively. This indicates a significant underperformance in generating profits from the asset base during these years. The 2017 value is particularly concerning, representing a substantial decline in profitability.
Improvement and Growth (2018-2020)
A clear upward trend emerged from 2018 to 2020. The ROA increased from 3.53% in 2018 to 6.20% in 2020, demonstrating improved asset efficiency and profitability. This period suggests successful strategic adjustments or favorable market conditions.
Strong Performance and Peak (2021-2023)
The ROA continued its positive trajectory, reaching 9.40% in 2021 and 9.31% in 2022. A significant peak was observed in 2023, with the ROA reaching 16.46%, indicating exceptionally efficient asset utilization and strong profitability. This represents the highest ROA value observed throughout the entire period.
Recent Trend (2024-2025)
Following the peak in 2023, the ROA decreased to 7.52% in 2024 and 6.524% in 2025. While still representing a reasonable level of profitability, this decline suggests a potential moderation of the strong performance experienced in the preceding year. Further investigation would be needed to determine the underlying causes of this recent shift.

Comparison to Competitors

Abbott Laboratories, ROA, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Health Care Equipment & Services)

Abbott Laboratories, ROA, long-term trends, comparison to sector (health care equipment & services)

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)